Published in Am J Gastroenterol on October 01, 2002
Treatment of uncomplicated reflux disease. World J Gastroenterol (2005) 0.85
Overlap of functional dyspepsia and GERD--diagnostic and treatment implications. Nat Rev Gastroenterol Hepatol (2013) 0.84
Prevalence of overweightedness in patients with gastro-esophageal reflux. World J Gastroenterol (2007) 0.81
Regional Variability of Repeat Esophagogastroduodenoscopy Use in the National Veteran Population. Dig Dis Sci (2017) 0.75
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet (2011) 6.77
The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet (2009) 5.65
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet (2012) 5.12
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med (2008) 3.76
Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet (2012) 3.19
Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. Gastroenterology (2002) 2.99
The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer (2008) 2.95
Low-level microsatellite instability in most colorectal carcinomas. Cancer Res (2002) 2.87
Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut (2013) 2.86
Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology (2005) 2.80
Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet (2003) 2.43
Explaining the familial colorectal cancer risk associated with mismatch repair (MMR)-deficient and MMR-stable tumors. Clin Cancer Res (2007) 2.24
Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis (2008) 2.22
Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. Hepatology (2014) 2.17
SMAD4 levels and response to 5-fluorouracil in colorectal cancer. Clin Cancer Res (2005) 2.05
Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology (2008) 1.98
Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol (2009) 1.92
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet (2013) 1.83
Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis (2008) 1.69
Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer (2007) 1.67
IL-23/IL-17 immunity as a hallmark of Crohn's disease. Inflamm Bowel Dis (2008) 1.66
Allelic imbalance at rs6983267 suggests selection of the risk allele in somatic colorectal tumor evolution. Cancer Res (2008) 1.59
Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer. Gastroenterology (2005) 1.56
A randomized comparison of target-controlled propofol infusion and patient-controlled sedation during ERCP. Endoscopy (2013) 1.50
SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res (2005) 1.50
Biliary dysplasia in patients with primary sclerosing cholangitis: additional value of DNA ploidity. Liver Int (2011) 1.48
Proportion and phenotype of MYH-associated colorectal neoplasia in a population-based series of Finnish colorectal cancer patients. Am J Pathol (2003) 1.38
Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Am J Pathol (2004) 1.37
Effectiveness of computerized decision support systems linked to electronic health records: a systematic review and meta-analysis. Am J Public Health (2014) 1.30
Large genomic rearrangements and germline epimutations in Lynch syndrome. Int J Cancer (2009) 1.24
Genetic alterations in the peritumoral stromal cells of malignant and borderline epithelial ovarian tumors as indicated by allelic imbalance on chromosome 3p. Int J Cancer (2004) 1.23
Sharing genetic risk with next generation: mutation-positive parents' communication with their offspring in Lynch Syndrome. Fam Cancer (2011) 1.23
Prevalence of adenomas and hyperplastic polyps in mismatch repair mutation carriers among CAPP2 participants: report by the colorectal adenoma/carcinoma prevention programme 2. J Clin Oncol (2008) 1.23
Comprehensive characterization of HNPCC-related colorectal cancers reveals striking molecular features in families with no germline mismatch repair gene mutations. Oncogene (2005) 1.22
Refining a taxonomy for guideline implementation: results of an exercise in abstract classification. Implement Sci (2013) 1.20
Association of IL23R, TNFRSF1A, and HLA-DRB1*0103 allele variants with inflammatory bowel disease phenotypes in the Finnish population. Inflamm Bowel Dis (2008) 1.20
Unregulated smooth-muscle myosin in human intestinal neoplasia. Proc Natl Acad Sci U S A (2008) 1.20
Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol (2010) 1.19
Altered expression of MLH1, MSH2, and MSH6 in predisposition to hereditary nonpolyposis colorectal cancer. J Clin Oncol (2003) 1.18
Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology (2010) 1.18
Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology (2010) 1.17
Oxidative stress has a role in malignant transformation in Barrett's oesophagus. Int J Cancer (2002) 1.16
Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scand J Gastroenterol (2012) 1.16
Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis (2012) 1.13
Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology (2005) 1.12
The genetics of HNPCC: application to diagnosis and screening. Crit Rev Oncol Hematol (2006) 1.11
The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. J Clin Epidemiol (2013) 1.11
Clinical decision support must be useful, functional is not enough: a qualitative study of computer-based clinical decision support in primary care. BMC Health Serv Res (2012) 1.10
BMPR1A mutations in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology (2011) 1.10
Candidate driver genes in microsatellite-unstable colorectal cancer. Int J Cancer (2011) 1.08
Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. J Infect Dis (2011) 1.08
Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia. Clin Cancer Res (2009) 1.07
IL23R in the Swedish, Finnish, Hungarian and Italian populations: association with IBD and psoriasis, and linkage to celiac disease. BMC Med Genet (2009) 1.06
PepT1 oligopeptide transporter (SLC15A1) gene polymorphism in inflammatory bowel disease. Inflamm Bowel Dis (2009) 1.06
Breast carcinoma and Lynch syndrome: molecular analysis of tumors arising in mutation carriers, non-carriers, and sporadic cases. Breast Cancer Res (2012) 1.05
Frequent gene dosage alterations in stromal cells of epithelial ovarian carcinomas. Int J Cancer (2006) 1.05
Elevated hyaluronan concentration without hyaluronidase activation in malignant epithelial ovarian tumors. Cancer Res (2002) 1.03
Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer. Int J Cancer (2014) 1.02
Preferential amplification of AURKA 91A (Ile31) in familial colorectal cancers. Int J Cancer (2006) 1.02
Patient and public attitudes to and awareness of clinical practice guidelines: a systematic review with thematic and narrative syntheses. BMC Health Serv Res (2014) 1.01
Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet Oncol (2012) 1.01
Low-penetrance susceptibility variants in familial colorectal cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.01
p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res (2005) 1.01
Background mutation frequency in microsatellite-unstable colorectal cancer. Cancer Res (2007) 1.00
Carbonic anhydrase IX is highly expressed in hereditary nonpolyposis colorectal cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.00
Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis (2011) 0.99
Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scand J Gastroenterol (2013) 0.99
#CochraneTech: technology and the future of systematic reviews. Cochrane Database Syst Rev (2014) 0.99
Eleven candidate susceptibility genes for common familial colorectal cancer. PLoS Genet (2013) 0.98
Electronic primary care guidelines with links to Cochrane reviews--EBM Guidelines. Fam Pract (2005) 0.98
Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission. Inflamm Bowel Dis (2014) 0.97
Colorectal pretumor progression before and after loss of DNA mismatch repair. Am J Pathol (2004) 0.97
BRAF mutation in sporadic colorectal cancer and Lynch syndrome. Virchows Arch (2013) 0.96
EXO1 variants occur commonly in normal population: evidence against a role in hereditary nonpolyposis colorectal cancer. Cancer Res (2003) 0.94
Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. PLoS One (2012) 0.94
A prospective randomized controlled multicenter trial comparing antibiotic therapy with appendectomy in the treatment of uncomplicated acute appendicitis (APPAC trial). BMC Surg (2013) 0.94
Mutations in the circadian gene CLOCK in colorectal cancer. Mol Cancer Res (2010) 0.93
Little evidence for involvement of MLH3 in colorectal cancer predisposition. Int J Cancer (2003) 0.93
Causes of death of mutation carriers in Finnish Lynch syndrome families. Fam Cancer (2012) 0.92
Primary care guidelines on consultation practices: the effectiveness of computerized versus paper-based versions. A cluster randomized controlled trial among newly qualified primary care physicians. Int J Technol Assess Health Care (2002) 0.92
Identification of candidate oncogenes in human colorectal cancers with microsatellite instability. Gastroenterology (2013) 0.92
NOD2 3020insC alone is not sufficient for colorectal cancer predisposition. Cancer Res (2004) 0.92
EBMPracticeNet: A Bilingual National Electronic Point-Of-Care Project for Retrieval of Evidence-Based Clinical Guideline Information and Decision Support. JMIR Res Protoc (2013) 0.92
Compliance and Satisfaction with Long-Term Surveillance in Finnish HNPCC Families. Fam Cancer (2006) 0.92
Systematic search for enhancer elements and somatic allelic imbalance at seven low-penetrance colorectal cancer predisposition loci. BMC Med Genet (2011) 0.91
PolyA deletions in hereditary nonpolyposis colorectal cancer: mutations before a gatekeeper. Am J Pathol (2002) 0.90
Patient-specific computer-based decision support in primary healthcare--a randomized trial. Implement Sci (2014) 0.90
A novel functionally deficient MYH variant in individuals with colorectal adenomatous polyposis. Hum Mutat (2005) 0.90
Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD. Inflamm Bowel Dis (2010) 0.90
Quality of life following laparoscopic Nissen fundoplication: assessing short-term and long-term outcomes. World J Gastroenterol (2013) 0.90
Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy. Scand J Gastroenterol (2012) 0.90
Somatic mutations and germline sequence variants in patients with familial colorectal cancer. Int J Cancer (2010) 0.89
Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas. Hum Mutat (2014) 0.89
Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse. Scand J Gastroenterol (2013) 0.88
Exome sequencing in diagnostic evaluation of colorectal cancer predisposition in young patients. Scand J Gastroenterol (2013) 0.88
Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers. Eur J Gastroenterol Hepatol (2005) 0.88
Recessively inherited right atrial isomerism caused by mutations in growth/differentiation factor 1 (GDF1). Hum Mol Genet (2010) 0.87